Clinical Trials in Ohio

Showing 17321-17340 of 20,938 trials

Liposomal Doxorubicin, Vincristine, & Dexamethasone Plus Arsenic Trioxide in Untreated Symptomatic Multiple Myeloma

NCT00201695

This study will assess the ability of Doxorubicin, Vincristine and Dexamethasone plus arsenic trioxide to achieve an overall response rate of greater than 60%.

Multiple Myeloma

Ohio State University Comprehensive Cancer Center12 participantsStarted Jul 2004

Columbus, Ohio, United States

WITHDRAWN32 miles

Identifiable Factors That May Lead to Postoperative Nausea and Vomiting After Simple Laparoscopic Appendectomy

NCT02044640

This is a retrospective chart review meant to identify any factors that are correlated with and may possibly lead to postoperative nausea and vomiting in order to predict need for longer hospital stays and potentially decrease postoperative nausea and vomiting.

Acute Appendicitis

Brian KenneyStarted Dec 2013

Columbus, Ohio, United States

TERMINATEDPhase 132 miles

PEG-Interferon Alfa-2b and Sorafenib in Treating Patients With Unresectable or Metastatic Kidney Cancer

NCT00589550

RATIONALE: PEG-interferon alfa-2b may interfere with the growth of tumor cells. Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It may also stop the growth of kidney cancer by blocking blood flow to the tumor. Giving PEG-interferon alfa-2b together with sorafenib may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of PEG-interferon alfa-2b and sorafenib in treating patients with unresectable or metastatic kidney cancer.

Kidney Cancer

Thomas Olencki1 participantsStarted Feb 2008

Columbus, Ohio, United States

Liposomal Doxorubicin, Vincristine, & Dexamethasone Plus Arsenic Trioxide in Untreated Symptomatic Multiple Myeloma

Identifiable Factors That May Lead to Postoperative Nausea and Vomiting After Simple Laparoscopic Appendectomy

PEG-Interferon Alfa-2b and Sorafenib in Treating Patients With Unresectable or Metastatic Kidney Cancer

Find Trials by Condition in Ohio

Cognitive Therapy in Reducing Depression in Patients With Cancer

Open-Label Assessment of the Albuterol Spiromax® Dry Powder Inhaler (DPI)

Prevention of Seasonal Affective Disorder

Growth Observational Study

Early Surfactant to Reduce Use of Mechanical Breathing in Low Birth Weight Infants

Development of Standards for the New Ballard Maturation Score

Airway Epithelium Gene Expression: AEGIS IDE

Study of EBI-005 in Dry Eye Disease (DED)

A Trial of Degarelix in Men With Lower Urinary Tract Symptoms (LUTS) Associated With Benign Prostatic Hyperplasia (BPH)

Carboplatin, Docetaxel, Bevacizumab, and Erlotinib Versus Chemotherapy Alone in Resected NSCLC

Red Cell Storage Duration Study

CCI-779 in Treating Patients With Metastatic Melanoma

Treatment for Subjects With Unresectable Stage III or Stage IV Melanoma

Efficacy of a 12-Week Regimen of Telaprevir, Pegylated Interferon, and Ribavirin in Treatment-Naive and Prior Relapser Subjects With Interleukin28B (IL28B) CC Genotype

Safety Trial of Naproxen Sodium/ Diphenhydramine

ALLPS VERSUS PVO Randomized Controlled Trial

Study To Compare On-Demand Treatment To A Prophylaxis Regimen Of BeneFIX In Subjects With Moderately Severe to Severe Hemophilia B